Literature DB >> 31414257

Inflammatory Breast Cancer: a Separate Entity.

Jennifer M Rosenbluth1, Beth A Overmoyer2.   

Abstract

PURPOSE OF REVIEW: Inflammatory breast cancer (IBC) is an uncommon but highly aggressive subtype of breast cancer that contributes significantly to breast cancer-related mortality. In this review, we provide an overview of the clinical and molecular characteristics of IBC, and highlight some areas of need for ongoing research. RECENT
FINDINGS: The disease is characterized by florid tumor emboli that obstruct dermal lymphatics, leading to swelling and inflammation of the affected breast. Recent studies have focused on tumor cell intrinsic features, such as signaling through pathways involved in growth and stem-like behavior, as well as extrinsic features, such as the immune system, that can be leveraged to develop new potential therapies. Key efforts have led to an increase in awareness of the disease as well as new insights into IBC pathogenesis. However, there is a strong need for new therapies designed specifically for IBC, and many unanswered questions remain.

Entities:  

Keywords:  Clinical trials; Dermal lymphatic invasion; Inflammatory breast cancer; Locally advanced breast cancer; Tumor emboli

Mesh:

Year:  2019        PMID: 31414257     DOI: 10.1007/s11912-019-0842-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  76 in total

1.  The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.

Authors:  Sabin B Motwani; Eric A Strom; Naomi R Schechter; Charles E Butler; Gordon K Lee; Howard N Langstein; Steven J Kronowitz; Funda Meric-Bernstam; Nuhad K Ibrahim; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

2.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

3.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.

Authors:  Kenneth L van Golen; LiWei Bao; Melinda M DiVito; ZhiFen Wu; George C Prendergast; Sofia D Merajver
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

4.  Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

Authors:  Vered Stearns; C Alexander Ewing; Rebecca Slack; Marie F Penannen; Daniel F Hayes; Theodore N Tsangaris
Journal:  Ann Surg Oncol       Date:  2002-04       Impact factor: 5.344

5.  Immediate breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvant chemotherapy is not delayed.

Authors:  Melinda M Mortenson; Philip D Schneider; Vijay P Khatri; Thomas R Stevenson; Thomas P Whetzel; Eiler J Sommerhaug; James E Goodnight; Richard J Bold
Journal:  Arch Surg       Date:  2004-09

6.  Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.

Authors:  Kenneth L van Golen; Li Wei Bao; Quintin Pan; Fred R Miller; Zhi Fen Wu; Sofia D Merajver
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.

Authors:  Yi Xiao; Yin Ye; Kurtis Yearsley; Susie Jones; Sanford H Barsky
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

8.  Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Authors:  Dongwei Zhang; Tiffany A LaFortune; Savitri Krishnamurthy; Francisco J Esteva; Massimo Cristofanilli; Ping Liu; Anthony Lucci; Balraj Singh; Mien-Chie Hung; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

9.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

Authors:  Ian J Bristol; Wendy A Woodward; Eric A Strom; Massimo Cristofanilli; Delora Domain; S Eva Singletary; George H Perkins; Julia L Oh; Tse-Kuan Yu; Welela Terrefe; Aysegul A Sahin; Kelly K Hunt; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

10.  High incidence of HER-2 positivity in inflammatory breast cancer.

Authors:  M Parton; M Dowsett; S Ashley; M Hills; F Lowe; I E Smith
Journal:  Breast       Date:  2004-04       Impact factor: 4.380

View more
  8 in total

1.  Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?

Authors:  Theresa Relation; Yaming Li; James L Fisher; Allan Tsung; Bridget Oppong; Mariam F Eskander; Samilia Obeng-Gyasi
Journal:  Surgery       Date:  2021-11-30       Impact factor: 3.982

2.  High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer.

Authors:  Ila Pant; Luca Grumolato; Anita Rogic; Ruben Fernandez-Rodriguez; Andrew Edwards; Suvendu Das; Aaron Sun; Shen Yao; Rui Qiao; Shabnam Jaffer; Ravi Sachidanandam; Guray Akturk; Rosa Karlic; Mihaela Skobe; Stuart A Aaronson
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

Review 3.  Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.

Authors:  R Jagsi; G Mason; B A Overmoyer; W A Woodward; S Badve; R J Schneider; J E Lang; M Alpaugh; K P Williams; D Vaught; A Smith; K Smith; K D Miller
Journal:  Breast Cancer Res Treat       Date:  2022-01-01       Impact factor: 4.872

4.  Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.

Authors:  Riley J Morrow; Amr H Allam; Belinda Yeo; Siddhartha Deb; Carmel Murone; Elgene Lim; Cameron N Johnstone; Matthias Ernst
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.639

Review 5.  A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs.

Authors:  Valeria Villarreal-García; José Roberto Estupiñan-Jiménez; Pablo E Vivas-Mejía; Vianey Gonzalez-Villasana; José Manuel Vázquez-Guillén; Diana Reséndez-Pérez
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

Review 6.  Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.

Authors:  Flavia Lima Costa Faldoni; Cláudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

7.  Literature-Wide Association Studies (LWAS) for a Rare Disease: Drug Repurposing for Inflammatory Breast Cancer.

Authors:  Xiaojia Ji; Chunming Jin; Xialan Dong; Maria S Dixon; Kevin P Williams; Weifan Zheng
Journal:  Molecules       Date:  2020-08-28       Impact factor: 4.411

8.  Inflammatory breast cancer appearance at presentation is associated with overall survival.

Authors:  Wintana Balema; Diane Liu; Yu Shen; Randa El-Zein; Bisrat G Debeb; Megumi Kai; Beth Overmoyer; Kathy D Miller; Huong T Le-Petross; Naoto T Ueno; Wendy A Woodward
Journal:  Cancer Med       Date:  2021-07-30       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.